Impact of Tildrakizumab on Patient Reported Outcomes in Patients With Moderate-to-severe Psoriasis in Canada
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Psoriasis (PsO), Moderate to Severe Psoriasis. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Canada
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
A Real-world, Longitudinal Observational Study of the Impact of Tildrakizumab on Patient Reported Outcomes in Patients With Moderate-to-severe Psoriasis in Canada
Overview
This is a multi-centre, non-interventional, open-label, prospective observational study that will be conducted across Canada over 52-week duration. Approximately 80 patients who are initiating tildrakizumab as part of their routine care through the ILUMYA SUPPORT® Program and meet the study's eligibility criteria will be enrolled. Specifically, the study will enroll patients with Fitzpatrick scale skin types III and above. The real-world impact, safety and effectiveness of tildrakizumab on patients with moderate-to-severe plaque psoriasis (PsO) remain largely undocumented in Canada, despite its approval in 2018. Given Canada's diverse population, this study presents an opportunity to evaluate tildrakizumab's quality of life, safety and effectiveness in specific demographic groups, particularly those patients with Fitzpatrick scale skin type III and above. The findings from this study will help optimize care, address unmet needs, and ensure that treatment outcomes are inclusive and reflective of Canada's diverse population.
Primary outcome measures
- Evaluate the impact of tildrakizumab on the Dermatology Life Quality Index (DLQI and DLQI-R) in patients of Fitzpatrick skin type III and above to 16 weeks [Time frame: 16 weeks]
Secondary outcome measures (11)
- Evaluate the impact of tildrakizumab on DLQI and DLQI-R in patients of Fitzpatrick skin type III and above to 52 weeks [Time frame: 52 weeks]
- Evaluate efficacy of tildrakizumab using Psoriasis Area Severity Index (PASI) in patients with Fitzpatrick skin types III and above [Time frame: Week 16, Week 52]
- Evaluate efficacy of tildrakizumab using Body Surface Area (BSA) in patients with Fitzpatrick skin types III and above [Time frame: Week 16, Week 52]
- Evaluate efficacy of tildrakizumab using static Physician Global Assessment (sPGA) in patients with Fitzpatrick skin types III and above [Time frame: Week 16, Week 52]
- Impact of tildrakizumab treatment on quality of life [Time frame: Week 16, Week 52]
- Impact of tildrakizumab treatment on sleep [Time frame: Week 16, Week 52]
- Impact of tildrakizumab treatment on discomfort [Time frame: Week 16, Week 52]
- Impact of tildrakizumab on skin pain [Time frame: Week 16, Week 52]
- Evaluate the correlation between clinical improvement (PASI, BSA, sPGA) and QoL outcomes, identifying how improvements in disease severity align with enhancements in QoL measures. [Time frame: Week 16, Week 52]
- Evaluate the safety of tildrakizumab over the course of the study [Time frame: Baseline to Week 52]
- Assess patient adherence and satisfaction with tildrakizumab treatment [Time frame: Baseline to Week 52]
Eligibility criteria
Inclusion criteria
- Adults aged 18 years or older.
- Diagnosis of moderate-to-severe chronic plaque-type PsO with Fitzpatrick scale type III or above (BSA >/=3%).
- Candidate for phototherapy and/or systemic therapy.
- Planning to initiate tildrakizumab as part of routine clinical care through the ILUMYA SUPPORT® Program for the treatment of plaque PsO but has not yet received their first dose.
a. Decision to treat with tildrakizumab must be made independently of and prior to study recruitment.
- Must be able to read, understand, and communicate in English.
- Must be willing to participate in the study and capable to provide informed consent
- Able to comply with all study procedures and attend all study visits
Exclusion criteria
- Known hypersensitivity to tildrakizumab, its excipients, or components of the container, as outlined in the Product Monograph.
- Concurrently taking any oral medication for treatment of PsO (e.g. methotrexate, cyclosporin, acitretin)
- Diagnosis of only palmoplantar psoriasis
- Concurrent medical condition or significant comorbidities that, in the investigator's opinion, would prevent participation in the study or interfere with study assessments
- Women of childbearing potential who are pregnant, planning to become pregnant, or breastfeeding.
- Prior (within 30 days) or actively participating in other interventional clinical trial(s).
- Unable or unwilling to comply with study procedures including completing questionnaire.
- Any other condition that, in the opinion of the investigator, could create a hazard to the participant's safety, endanger the study procedures, or interfere with the interpretation of study results
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Canada · 6 centers
- Burlington Skin and Wellness — Burlington
- Locke Dermatology — Hamilton
- Panorama Dermatology Clinic — Kanata
- Centricity Research London Victoria Multispecialty — London
- Factor Dermatology — Ottawa
- Saskatoon Dermatology Centre — Saskatoon
Identifiers
NCT: NCT07370766 · PRO/PsO-01